Payment overview · 2025
General Payments
$406.12
12 reported records · 6 companies
Healthcare provider profile · identity verified
Peter Seth Morrison, M.D.
Allopathic & Osteopathic Physicians|Pain Medicine|Pain Medicine · CANTON, GA · NPI 1689785073
Verified facts
What the public records show
CMS Open Payments records show Peter Seth Morrison, M.D. received $406.12 in general payments during 2025 across 12 reported records.
Medtronic, Inc. accounted for 23.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Movantik, Prolate, Qulipta, Relistor, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Ubrelvy by this doctor in 2024.
Forte Bio-Pharma LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLATE as an associated drug or biological on 5557 records involving 1112 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Prolate by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RELISTOR as an associated drug or biological on 23206 records involving 6246 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Relistor by this doctor in 2024.
Valinor Pharma, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOVANTIK as an associated drug or biological on 4139 records involving 1847 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Movantik by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$93.93 | 23.1% | 1 | 2025 |
| SPR Therapeutics, Inc | Unresolved — no canonical attribution shown | $93.93 | 23.1% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $89.14 | 21.9% | 4 | 2025 |
| Forte Bio-Pharma LLC | Unresolved — no canonical attribution shown | $76.09 | 18.7% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.38 | 8.7% | 2 | 2025 |
| Valinor Pharma, LLC | Unresolved — no canonical attribution shown | $17.65 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $406.12 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| INTELLIS ADAPTIVESTIM Normalized: intellis adaptivestim |
Device | Medtronic, Inc. | $93.93 | 1 | 2025 |
Source payment records
|
|||||
| SPRINT PNS System Normalized: sprint pns system |
Device | SPR Therapeutics, Inc | $93.93 | 1 | 2025 |
Source payment records
|
|||||
| NALOCET Normalized: nalocet |
Drug | Forte Bio-Pharma LLC | $76.09 | 3 | 2025 |
Source payment records
|
|||||
| PROLATE Normalized: prolate |
Drug | Forte Bio-Pharma LLC | $76.09 | 3 | 2025 |
Source payment records
|
|||||
| TANLOR Normalized: tanlor |
Drug | Forte Bio-Pharma LLC | $76.09 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $54.64 | 3 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.38 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $34.50 | 1 | 2025 |
Source payment records
|
|||||
| MOVANTIK Normalized: movantik |
Drug | Valinor Pharma, LLC | $17.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOVANTIK movantik |
2025 | Movantik | 2024 | 128 | exact normalized | Medicare Part D |
| PROLATE prolate |
2025 | Prolate | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RELISTOR relistor |
2025 | Relistor | 2024 | 94 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Forte Bio-Pharma LLC Exact reporting entity; no affiliate inference |
2025 | PROLATE open payments reported associated product |
CMS Open Payments — General Payments 5557 supporting records · 1112 recipient NPIs · example record 1251429153 |
Prolate · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | RELISTOR open payments reported associated product |
CMS Open Payments — General Payments 23206 supporting records · 6246 recipient NPIs · example record 1231775437 |
Relistor · 2024 Exact normalized brand match · 1 Part D row |
94 | 18 |
| Valinor Pharma, LLC Exact reporting entity; no affiliate inference |
2025 | MOVANTIK open payments reported associated product |
CMS Open Payments — General Payments 4139 supporting records · 1847 recipient NPIs · example record 1248445875 |
Movantik · 2024 Exact normalized brand match · 1 Part D row |
128 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 2018 | 252 |
| Oxycodone Hcl | Oxycodone Hcl | 1899 | 226 |
| Gabapentin | Gabapentin | 1578 | 199 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1540 | 200 |
| Morphine Sulfate Er | Morphine Sulfate | 881 | 98 |
| Alprazolam | Alprazolam | 616 | 80 |
| Pregabalin | Pregabalin | 606 | 86 |
| Promethazine Hcl | Promethazine Hcl | 588 | 90 |
| Tizanidine Hcl | Tizanidine Hcl | 576 | 82 |
| Methadone Hcl | Methadone Hcl | 442 | 48 |
| Carisoprodol | Carisoprodol | 424 | 53 |
| Fentanyl | Fentanyl | 386 | 48 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 379 | 57 |
| Clonazepam | Clonazepam | 324 | 39 |
| Naloxone Hcl | Naloxone Hcl | 292 | 287 |
| Xtampza Er | Oxycodone Myristate | 292 | 34 |
| Ondansetron Odt | Ondansetron | 287 | 48 |
| Tramadol Hcl | Tramadol Hcl | 247 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 244 | 28 |
| Famotidine | Famotidine | 195 | 39 |
| Lidocaine | Lidocaine | 173 | 27 |
| Morphine Sulfate | Morphine Sulfate | 163 | 22 |
| Methocarbamol | Methocarbamol | 162 | 20 |
| Hydromorphone Hcl | Hydromorphone Hcl | 158 | 29 |
| Baclofen | Baclofen | 157 | 19 |
| Ibuprofen | Ibuprofen | 154 | 27 |
| Ondansetron Hcl | Ondansetron Hcl | 142 | 20 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 137 | 18 |
| Trazodone Hcl | Trazodone Hcl | 137 | 16 |
| Methylprednisolone | Methylprednisolone | 134 | 113 |
| Movantik | Naloxegol Oxalate | 128 | 28 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 125 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 14 |
| Lorazepam | Lorazepam | 109 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 106 | 28 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 102 | 14 |
| Temazepam | Temazepam | 101 | 12 |
| Topiramate | Topiramate | 99 | 11 |
| Celecoxib | Celecoxib | 97 | 17 |
| Diazepam | Diazepam | 96 | 14 |
| Relistor | Methylnaltrexone Bromide | 94 | 18 |
| Oxycontin | Oxycodone Hcl | 89 | 11 |
| Symproic | Naldemedine Tosylate | 81 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 69 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 68 | suppressed |
| Omeprazole | Omeprazole | 65 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 55 | suppressed |
| Belsomra | Suvorexant | 54 | 18 |
| Sertraline Hcl | Sertraline Hcl | 52 | suppressed |
| Ztlido | Lidocaine | 51 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 50 | suppressed |
| Buprenorphine | Buprenorphine | 49 | suppressed |
| Ubrelvy | Ubrogepant | 48 | suppressed |
| Lubiprostone | Lubiprostone | 47 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 46 | suppressed |
| Meloxicam | Meloxicam | 45 | suppressed |
| Dronabinol | Dronabinol | 43 | suppressed |
| Nucynta Er | Tapentadol Hcl | 37 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 35 | suppressed |
| Eszopiclone | Eszopiclone | 31 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Belbuca | Buprenorphine Hcl | 22 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 22 | suppressed |
| Hysingla Er | Hydrocodone Bitartrate | 21 | suppressed |
| Horizant | Gabapentin Enacarbil | 20 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 19 | suppressed |
| Endocet | Oxycodone Hcl/Acetaminophen | 19 | suppressed |
| Triazolam | Triazolam | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 16 | suppressed |
| Nucynta | Tapentadol Hcl | 15 | suppressed |
| Topiramate Er | Topiramate | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Savella | Milnacipran Hcl | 13 | suppressed |
| Chlorzoxazone | Chlorzoxazone | 12 | suppressed |
| Hydrocodone Bitartrate Er | Hydrocodone Bitartrate | 12 | suppressed |
| Hydromorphone Er | Hydromorphone Hcl | 12 | suppressed |
| Prolate | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Qulipta | Atogepant | 12 | suppressed |
| Quviviq | Daridorexant Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 11 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 11 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406.12 · 12 records | Medtronic, Inc. | INTELLIS ADAPTIVESTIM, MOVANTIK, NALOCET, PROLATE, QULIPTA, RELISTOR, SPRINT PNS System, TANLOR, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Movantik play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error